Table B/LEN-R combinations in MCL (phase... | American Society of Hematology

Table

B/LEN-R combinations in MCL (phase 2/3 trials >20 patients)

Ref.	Regimen	Study type, phase	Line of therapy	Patient no.	OR, %	CR, %	PFS	OS
2	6× BR	3	First line	46	93	40	Median: 35.4 mo	N/A
3	6× BR	3	First line	36	94	50	N/A	N/A
1	6× BR + LEN	2	First line	51	80	64	Median: 42 mo	73% (36 mo)
4	6× BR + LEN	2	Relapse	42	79	58	Median: 20 mo	67% (24 mo)
5	R + LEN	2	First line	38	87	61	85% (2 y)	97% (24 mo)
6	R + LEN	2	Relapse	44	57	36	Median: 11.1 mo	Median: 24.3 mo

Ref.	Regimen	Study type, phase	Line of therapy	Patient no.	OR, %	CR, %	PFS	OS
2	6× BR	3	First line	46	93	40	Median: 35.4 mo	N/A
3	6× BR	3	First line	36	94	50	N/A	N/A
1	6× BR + LEN	2	First line	51	80	64	Median: 42 mo	73% (36 mo)
4	6× BR + LEN	2	Relapse	42	79	58	Median: 20 mo	67% (24 mo)
5	R + LEN	2	First line	38	87	61	85% (2 y)	97% (24 mo)
6	R + LEN	2	Relapse	44	57	36	Median: 11.1 mo	Median: 24.3 mo

CR, complete response; N/A, not available; OR, overall response; OS, overall survival; Ref., reference/citation number.